Regulatory NewsRegulatory News
Study: Accelerated approval pathway working as intended in most cases
Posted 10 August 2022 By Jeff Craven
Over the last several decades, the US Food and Drug Administration’s (FDA) accelerated approval program has largely been working as it was designed to, with about half the products using the pathway being converted to traditional approva...
Regulatory NewsRegulatory News
EMA, HMA outline evolution of DARWIN EU real-world database
Posted 02 August 2022 By Ferdous Al-Faruque
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) plan to launch an ambitious new database to collect real-world data (RWD) from a slew of studies that reviewers can reference for their regulatory decision-mak...
Regulatory NewsRegulatory News
FDA official: Patients play an increasing role in rare disease drug development
Posted 01 August 2022 By Mary Ellen Schneider
Patients have a critical role in drug development, from identifying unmet medical needs to assessing meaningful clinical benefits, according to Kerry Jo Lee, MD, associate director of rare diseases in the US Food and Drug Administration’...
Regulatory NewsRegulatory News
Continuous manufacturing applicants saw quicker approvals, higher revenue than batch applicants
Posted 06 July 2022 By Jeff Craven
Applicants that used continuous manufacturing (CM) technology to bring their products to market waited less time before approval after submission compared to batch manufacturing products, according to results from a US Food and Drug Admi...
Regulatory NewsRegulatory News
FDA approval lowers, but doesn’t eliminate disparities in immunotherapy use
Posted 30 June 2022 By Jeff Craven
Racial, ethnic and sociodemographic disparities that are present in clinical trials and compassionate use agreements for cancer immunotherapy during the pre-approval period are reduced, but not eliminated after the US Food and Drug Admin...
Regulatory NewsRegulatory News
RWD in clinical trials: External control arms take the lead
Posted 23 June 2022 By Mary Ellen Schneider
The US Food and Drug Administration (FDA) has now published four draft guidances spelling out how it will consider real-world data (RWD) in regulatory decision-making, from the use of electronic health records and registries to RWD in no...
Regulatory NewsRegulatory News
Expert proposes changes to accelerated approval reforms in user fee bills
Posted 08 June 2022 By Jeff Craven
With the Senate Committee on Health, Education, Labor and Pensions (HELP) recently releasing the Food and Drug Administration Safety and Landmark Advancements (FDASLA) act from committee, some stakeholders are proposing Congress make cha...
Regulatory NewsRegulatory News
FDA adds transition period to electromagnetic compatibility final guidance
Posted 06 June 2022 By Ferdous Al-Faruque
The US Food and Drug Administration (FDA) has finalized guidance on medical device electromagnetic compatibility that replaces a 2016 document on the same topic. While the agency is giving medical device sponsors 60 days to adopt the gui...
Online Course Online Course
Medical Device Certificate Elective Medical Device Certificate Elective
Medical Devices: Definition & Lifecycle [1.0 RAC]
1.0 RAC Credits
Member: $135.00 Nonmember: $185.00
This course acts as a primer—a basic introduction to medical devices and general aspects of product and regulatory lifecycles.
On-demand On-demand
Strategic Role of the RA Professional
1.0 RAC Credits
Member: $0.00 Nonmember: $20.00
This webcast will demonstrate how the RA professional is a key strategic player starting with premarket planning and continuing through product development stages, manufacturing, and post market activities.
On-demand On-demand
Regulatory Intelligence and Its Value in Regulated Industry
1.5 RAC Credits
Member: $0.00 Nonmember: $20.00
The fundamentals of global regulatory intelligence, and how it can be used to influence regulatory decision making throughout a development program and lifecycle management of a therapeutic product.
On-demand On-demand
AI for Post Market Surveillance Compliance and Regulatory Work According to MDR
1.5 RAC Credits
Member: $0.00 Nonmember: $20.00
Webcast registration includes access to handouts, presentation slides and the on-demand recording for one year.
E-books E-books
Orphan Drug Development for Rare Diseases (e-book)
Member: $130.00 Nonmember: $180.00
Orphan Drug Development for Rare Diseases covers every aspect of orphan drug development. Topics include incentives, benefits, patient engagement, designation, marketing authorization, and market access.
On-demand On-demand
2020 NMPA (CFDA) Key Updates and Look Ahead on 2021
1.0 RAC Credits
Member: $0.00 Nonmember: $20.00
How can manufacturers or inventors be proactively prepared to shorten their time to market for new submissions, allow enough lead time for renewal, and to know when to file for modifications to avoid penalties?
Online Course Online Course
Pharmaceutical Certificate Elective Pharmaceutical Certificate Elective
Regulation of Biosimilars [2.0 RAC]
2.0 RAC Credits
Member: $255.00 Nonmember: $350.00
This course is for regulatory professionals interested in biosimilar development and regulatory approval strategies.
Online Course Online Course
Medical Device Certificate Elective Medical Device Certificate Elective
Medical Devices: China, Japan, Singapore and South Korea Regulatory Overview [4.0 RAC]
4.0 RAC Credits
Member: $465.00 Nonmember: $640.00
This course examines and introduces medical device regulations and registration requirements in China, South Korea, Japan and Singapore.
     
  •  
  • 1
  •  
  • 2
  •  
  • 3
  •  
  • 4
  •  
  • 5
  •  
  •